“…Several studies demonstrated phosphorylation of 14-3-3 at two sites, e.g., 14-3-3 S58 and 14-3-3 T233, and proposed a regulatory role of these phosphorylations in 14-3-3 dimerization and target binding, respectively (Megidish et al, 1995;Dubois et al, 1997a,b;Megidish et al, 1998). While conducting the metabolic 32 P-labling experiments, we noticed that the dimerization-deficient 14-3-3 mutant contained significantly more 32 P than the wild-type 14-3-3; this difference was further enhanced by treatment of cells with EGF or the phosphatase inhibitor calyculin A, reaching up to 50-fold higher 32 P incorporation ( Figure 7A, compare lanes 1 and 6, basal; lanes 2 and 7, EGF; and lanes 4 and 5 with 9 and 10, calyculin A).…”